Migraine drug global sales decline The domestic market is expected to continue to grow

Qutan drugs, introduced in the 1990s, have driven the growth of the global market for anti-migraine drugs, which reached $3.5 billion by 2005. In recent years, the global market for anti-migraine drugs has been declining due to the availability of breakthrough anti-migraine drugs and the patented cliffs of seven quentin drugs that have been approved for sale.generics are shrinking the global market
data from IMS show that the global market for anti-migraine drugs has been on a downward trend for the past five years, but at a slower pace. The global market for anti-migraine drugs was $3,746 million in 2011 and $3,395 million in 2015, down 2.88 percent year-on-year. As can be seen from Table 1, no one of the world's migraine brand drugs exceeded $1 billion in sales in 2015. Even though the best-performing Relpax sales did not exceed $500 million, Relpax's core patent, US5545644, expired on December 26, 2016, and sales of Relpax are expected to decline over the next few years as generics enter the market.
Pernix's Treximet, the only compound approved by the U.S. FDA, exceeded $100 million in global sales in its 7th year (2015). In recent years, treximet is expected to continue to add value in the years ahead of the patent expiration with its good clinical efficacy and safety.the nascent domestic market
migraine medications include intermittent preventive treatment of headaches and onset of headaches, including over-the-counter and prescription drugs. Among them, there are many types of drugs available for preventive treatment of migraines, mainly analgesics, anti-epileptic drugs, antidepressants and anti-depressants. Some of these preventive treatment drugs are over-instructional. The drugs used to treat migraine attacks are mainly analgesics, anti-spitting drugs, keratonic and qutan drugs.
the current clinical treatment of migraine ketamine drugs are mainly ketamine caffeine tablets. Qutan-type drugs are currently the only type of drugs developed only for migraines, and their efficacy is better than that of ketamine-type drugs. In view of the current clinically available to prevent or treat migraine drugs, and involving a variety of drugs to expand the use of adaptive drugs, the author believes that the domestic market value of anti-migraine drugs is actually difficult to truly estimate.
of the eight drugs approved by the FDA in the U.S. that contain quertam, only AstraZeneta's Zomeptan is imported, and seven are not yet imported. With the exception of Treximet, although none of the remaining seven drugs is related to intellectual property issues, only Schumaputan, Zomeptuptan and Liza tuptan have been domesticated. It can be seen that both the original research company and local enterprises on migraine development in this area are conservative attitude.
data from Linghu Pharmaceutical News show that in recent years, the sales amount of sample hospitals in key cities of Qutan anti-migraine drugs in China has been increasing year by year, with sales amounting to 6.4178 million yuan in 2016, up 21.86 percent year-on-year. Among them, the market share of Schumaptan, Zomeptuptan and Liza tuptan was 0.95%, 29.64% and 69.41%, respectively.
compared with the global market for anti-migraine drugs, the domestic market for qutan-type anti-migraine drugs is just beginning. Comprehensive domestic qutan drug registration information, it is expected that in the next few years the domestic qutan class anti-migraine drug market will continue to grow, mainly because in the next few years there will be qutan drugs have been approved. Although a number of domestic enterprises have been approved Zomeptumputan, and the original Research AstraZene imports, but Zomeptumputan's domestic market performance is flat, nearly 70% of the domestic market is occupied by Liza Quptan.conclusions<<<
the pathological mechanism of migraine drugs is not fully clarified, so there is currently no drug that can completely cure migraines. Qutan is the only drug developed for migraines, but migraine drugs cannot be used for intermittent preventive treatment. Existing drugs do not meet clinical needs.
the global market for anti-migraine drugs has been flat in recent years due to the advent of non-breakthrough anti-migraine drugs. Compared with the global product structure and market, the domestic product structure is single, in the United States FDA approved for listing of 8 kinds of drugs containing qutan, only 3 kinds of domestic market, the remaining 5 are still in the registration and declaration stage, from the time of market is still a considerable distance. (Medical Economics)